Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOP1: Insulin Glargine U300 in T1DM
NCT03406000Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jan 2018
- Primary completion
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of insulin glargine in type 1 diabetes mellitus (T1D), sponsored by Sanofi. Primary endpoint: Mean change in Glycated Hemoglobin (HbA1c) at 24 weeks. Started Jan 2018; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03406000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03406000.